Semiconductors: Silicon Powerhouse
Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through the state-backed TSMC (Taiwan Semiconductor Manufacturing Company), the island functions as the world’s foundry, manufacturing the advanced chips designed by the likes of Apple, Nvidia and AMD.
By making chips to others’ specifications rather than designing them Taiwan has become irreplaceable in global technology supply chains, with the island accounting for over 60 percent of global foundry revenue and more than 90 percent of leading-edge chip manufacturing. Semiconductors now account for approximately one-fifth of Taiwan’s entire economy.
For healthcare and life sciences specifically, Taiwan’s semiconductor dominance creates a unique enabling environment: AI-driven drug discovery, digital pathology, and bionic medical devices all draw on the same supply chain, engineering talent, and precision manufacturing culture that built the chip industry.
However, the sector is also acutely geopolitically sensitive. The US has moved aggressively to restrict China’s access to advanced chips – which underpin both AI development and modern military capability – and Taiwan’s foundries sit at the centre of that contest, lying 180 kilometres off the Chinese mainland.
Capital Markets: The World’s Fifth Largest Stock Exchange
Driven by surging global demand for semiconductors, Taiwan’s stock market overtook India in May 2026 to become the world’s fifth largest by market capitalisation, at USD 4.95 trillion – behind only the US, mainland China, Japan, and Hong Kong.
That dominance comes with marked concentration: TSMC alone now accounts for approximately 42 percent of the benchmark index. The capital is increasingly international, too, with foreign investors now holding 44 percent of total market capitalisation – underpinning Taiwan’s ambition to position itself as an Asian Asset Management Centre.
Beneath the semiconductor-heavy Taiwan Stock Exchange sits a second-tier market that has become a critical financing engine for the island’s life sciences sector. The Taipei Exchange (TPEx) was established before its equivalents in Korea, Hong Kong and Japan in 1994 to serve small- and medium-sized innovators rather than large caps. Crucially for biotech, it allows pre-revenue companies to list on the basis of clinical and commercial potential rather than profitability.
Healthy Taiwan: From Sick-Care to Health-Care
If semiconductors define Taiwan’s economy, demographics increasingly define its healthcare policy; Taiwan has become a super-aged society while simultaneously recording one of the lowest birth rates on the planet. The resulting strain on the National Health Insurance system means that less than 18 percent of the population accounts for over 42 percent of total healthcare expenditure.
It is against this backdrop that physician-president Lai Ching-te launched his flagship ‘Healthy Taiwan’ initiative in 2024 – a comprehensive attempt to pivot the system from reactive ‘sick-care’ towards prevention and long-term sustainability.
Funding has followed; NHI annual budget growth soared from three to four percent to between six and 6.5 percent in 2025; a USD 310 million Cancer Drug Fund has been established to fast-track breakthrough oncology therapies, the national cancer screening budget has more than tripled, and a USD 1.56 billion ‘Cultivation Programme’ funds digital infrastructure, workforce, and long-term care.
The philosophy shift is tangible in the data – nationwide cancer screening is up more than 25 percent year-on-year, and a novel ‘Health Coins’ scheme even rewards citizens with redeemable points for healthy behaviours like exercise and screening attendance.
CDMOs: Seizing the China-Plus-One Moment
Taiwan’s contract manufacturers are also booming. With the US BIOSECURE Act blocking companies that receive federal funding from working with designated mainland Chinese manufacturers, many multinational pharmas are diversifying their manufacturing footprint via a ‘China-plus-one’ strategy.
Taiwan, with its PIC/S GMP credentials, deep manufacturing discipline, and proximity to both US and Asian markets, has positioned itself as a credible beneficiary. However, rather than chase the high-volume commodity manufacturing dominated by India, Korea, and mainland China, Taiwan is concentrating on advanced therapies: antibody-drug conjugates, mRNA, and cell and gene therapies (CGTs).
The bet is already drawing concrete commitments – GSK signed a USD 250 million manufacturing contract with local player Bora Pharmaceuticals in February 2026 – while a USD 750 million national ‘Medical Resilience’ fund subsidises domestic production of over 50 critical drugs through to 2029. The strategic logic borrows directly from the island’s semiconductor playbook, with the explicit ambition, in the words of one executive, of becoming the ‘TSMC of cell therapy.’
CGT Regulation: Second-Mover Advantage
If Taiwan’s CDMO ambitions in CGT are to succeed, they need a regulatory framework to match – and here the island has moved with unusual foresight. CGTs pose a regulatory challenge: pathways built around mass-produced chemical compounds fit awkwardly around bespoke, living therapies. Taiwan’s response has been to build a dedicated legal architecture, with the added benefit of having watched earlier regional movers stumble.
The 2024 Regenerative Medicine and Regenerative Medicinal Products Acts make Taiwan one of only two countries to have enacted a dedicated CGT framework. The legislation establishes a dual-track system separating hospital-led custom therapies from mass-manufactured products and allows conditional market approval based on Phase II data.
The design is pointedly informed by regional experience: Japan’s pioneering 2014 conditional pathway generated approvals that struggled to secure reimbursement, while South Korea built infrastructure rapidly only to see bureaucratic complexity blunt clinical translation. Taiwan’s framework embeds the post-marketing surveillance and clinical-commercial integration mechanisms that were absent in both.
Clinical Trials: Asia’s Trial Magnet
Underpinning much of Taiwan’s life sciences ambition is a clinical trials infrastructure that has become one of Asia’s most competitive. Taiwan combines a dense hospital network, universal health coverage, clinical talent, and operating costs below those of Japan, the EU, and the US – making it a magnet for early-phase and multinational studies alike.
Though smaller in absolute volume than the likes of Korea or China, Taiwan punches well above its weight on a per-capita basis; hosting over 900 registered trials a year against a population of just 23 million.
A 60-day IND approval pathway offers a meaningful speed advantage over regional peers, while the newly established Taiwan Alliance of Clinical Trial Centers – a 32-institution network operating under a unified protocol and single institutional review board – has materially accelerated recruitment timelines.
That clinical capacity is increasingly matched by molecular depth – NHI reimbursement of next-generation sequencing now spans 14 solid tumour categories and five haematological malignancies, while the Taiwan Precision Medicine Initiative has assembled genetic and clinical data from more than half a million participants.
